Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $25,700.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the transaction, the director now directly owns 922,334 shares of the company's stock, valued at $2,370,398.38. This represents a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anixa Biosciences Price Performance

NASDAQ ANIX traded down $0.17 during trading hours on Friday, reaching $2.41. 144,949 shares of the stock traded hands, compared to its average volume of 114,704. The stock has a 50 day simple moving average of $2.82 and a two-hundred day simple moving average of $3.02. Anixa Biosciences, Inc. has a 1 year low of $2.07 and a 1 year high of $5.13. The company has a market cap of $77.55 million, a price-to-earnings ratio of -6.18 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. On average, sell-side analysts forecast that Anixa Biosciences, Inc. will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Anixa Biosciences in the 3rd quarter worth $34,000. Concorde Asset Management LLC purchased a new position in shares of Anixa Biosciences in the second quarter worth about $31,000. Tyler Stone Wealth Management lifted its stake in shares of Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock valued at $132,000 after acquiring an additional 21,008 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock valued at $110,000 after acquiring an additional 21,100 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ANIX. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.